Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer

Journal article

Peer reviewed

U.A. Matulonis, B.J. Monk, A.A. Secord, M.A. Geller, D.S. Miller, N.G. Cloven, G.F. Fleming, A.E. Wahner Hendrickson, M. Azodi, P.A. DiSilvestro, …

Gynecologic oncology, Vol.154, pp.3-3

06/2019

Metrics

5 Record Views

Title: Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer
Creators: U.A. Matulonis - Harvard University
B.J. Monk - University of Arizona
A.A. Secord - Duke University Health System
M.A. Geller - University of Minnesota Medical Center
D.S. Miller - The University of Texas Southwestern Medical Center
N.G. Cloven - Texas Oncology
G.F. Fleming - University of Chicago
A.E. Wahner Hendrickson - Mayo Clinic in Arizona
M. Azodi - Yale University
P.A. DiSilvestro - Women & Infants Hospital of Rhode Island
A.M. Oza - Princess Margaret Cancer Centre
M. Cristea - City Of Hope National Medical Center
J.S. Berek - Cancer Prevention Institute of California
J.K. Chan - California Pacific, Palo Alto, CA, USA
Y. Li - Tesaro
K. Luptakova - Tesaro
S.J. Hazard - Tesaro
K.N. Moore - University of Oklahoma Health Sciences Center
Publication Details: Gynecologic oncology, Vol.154, pp.3-3
Publisher: Elsevier Inc
Identifiers: 991005969006802656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article